Evidence map›Paper›PMID 35389777›Full record

ArticleScience (New York, N.Y.)2022

Genome-wide analysis of somatic noncoding mutation patterns in cancer.

Felix Dietlein, Alex B Wang, Christian Fagre, Anran Tang, Nicolle J M Besselink, Edwin Cuppen, Chunliang Li, Shamil R Sunyaev, James T Neal, Eliezer M Van Allen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 111 citations in OpenAlex.

  1. Review
  2. Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Crosstalk BetweenCancers · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Felix DietleinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-6651-7155
Alex B Wang *Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0001-8678-5205
Christian Fagre *Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Anran Tang *Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Nicolle J M BesselinkCenter for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.ORCID 0000-0002-8961-4441
Edwin CuppenCenter for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.ORCID 0000-0002-0400-9542
Chunliang LiDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-5938-5510
Shamil R SunyaevDivision of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5715-5677
James T NealCancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-3962-8570
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-0201-4444
Broad Institute · USOncode Institute · NLBrigham and Women's Hospital · USSt. Jude Children's Research Hospital · US

Funding

Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
A pan-cancer atlas of driver mutations in >100,000 patients based on a hypothesis-driven combined computational and experimental approachR00CA262152 · NCI · BOSTON CHILDREN'S HOSPITAL · PI DIETLEIN, FELIX · 2022 to 2024
$712k
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regionsR21CA242861 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2019 to 2020
$603k
A pan-cancer atlas of driver mutations in >100,000 patients based on a hypothesis-driven combined computational and experimental approachK99CA262152 · NCI · DANA-FARBER CANCER INST · PI DIETLEIN, FELIX · 2021 to 2021
$133k
NCI NIH HHS K99 CA262152NCI NIH HHS R00 CA262152NCI NIH HHS R01 CA227388NCI NIH HHS R21 CA242861
6 · The paper itself

Abstract

We established a genome-wide compendium of somatic mutation events in 3949 whole cancer genomes representing 19 tumor types. Protein-coding events captured well-established drivers. Noncoding events near tissue-specific genes, such as

Indexed as

NeoplasmsPromoter Regions, GeneticDNA Mutational AnalysisGene Expression Regulation, NeoplasticHumansMaleMutationOncogenesRegulatory Sequences, Nucleic AcidX-Box Binding Protein 1X-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID35389777
PMCPMC9092060
OpenAlexW4224006698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.